Medical Technology: approx. 70%
Energy and Industry: approx. 20%
Other: approx. 10%

TOP 3 Markets:

1. USA: approx. 50%
2. Europe: approx. 30%
3. Asia-Pacific: approx. 15%

Integer Holdings Corporation generates the majority of its revenue from the medical technology industry, particularly through the manufacturing of devices and components for medical applications. The USA remains the largest market for the company, followed by Europe and the Asia-Pacific region, which together account for the majority of international revenues.

This distribution reflects Integer's strong presence in the medical technology sector, with the USA as its home market making up the largest share. The expansion into Europe and Asia-Pacific demonstrates the company's efforts to increase global reach.

Production Sites of Integer Holdings Corporation:

Integer Holdings Corporation operates production facilities in several countries worldwide, including:

• USA: Multiple locations, including in Texas and New York.
• Mexico: Significant production capacities.
• Ireland: Production site for European markets.
• Switzerland: Specialized manufacturing facilities.
• Costa Rica: Key location for the production of medical devices.

Integer Holdings is a leading provider of medical devices and components, leveraging its global production sites to ensure efficient supply to its customers. The strategic placement of the plants enables the company to effectively serve both local and international markets.

Revenue Growth: Estimated at 8-10% annually (2026, based on industry trends)

Research & Development: Investments of about 7% of revenue (2025)

Integer Holdings Corporation pursues a growth strategy that heavily relies on innovation and expansion into new markets. The company continuously invests in research and development to expand its product range and leverage technological advancements. These investments account for approximately 7% of revenue and are intended to strengthen competitiveness in the medical technology industry.

Additionally, Integer focuses on strategic acquisitions and partnerships to broaden its market presence. This strategy aims to promote both organic and inorganic growth and expand geographical reach.

Another focus is on optimizing production processes and the supply chain to achieve efficiency improvements and enhance cost structure. This is intended to increase margins in the long term and ensure the company's financial stability.

Commodities/Materials: Metals, Plastics, Electronic Components

Main Import Countries: China, Mexico, Germany

Integer Holdings Corporation is a leading provider of medical devices and components, especially in the fields of cardiology and neuromodulation. The company imports various raw materials and materials that are essential for the production of their products.

Metals such as stainless steel and titanium are often imported from countries like China and Germany, as these countries have a strong metal processing industry. Plastics and electronic components often come from China and Mexico, where Integer also operates production facilities to optimize the supply chain and reduce costs.

Through global sourcing, Integer Holdings can benefit from the advantages of different markets, with the quality and cost of materials being crucial factors.

Market Share: Estimated 10-15% in the field of medical technology (2026)
R&D Investments: Approximately 7% of revenue (2025)
Patents: Over 1,000 active patents (2025)

Integer Holdings Corporation has a significant competitive advantage in the field of medical technology, particularly due to its strong position in manufacturing devices and components for cardiovascular and neuromodulatory therapy. The company consistently invests in research and development, accounting for about 7% of its revenue. These investments enable Integer to develop innovative products and continuously expand its product range.

Another key advantage is the extensive portfolio of over 1,000 active patents, providing Integer with protection against imitators and strengthening its market position. Strategic partnerships and long-term contracts with leading medical device manufacturers also contribute to the stability and growth of the company.

Overall, Integer Holdings positions itself as a leading player in the medical technology industry through technological innovations, a strong customer base, and an extensive patent portfolio.

Institutional Investor Share: 95% (2026, estimated)

Insider Buys/Sells: No significant transactions in the last 12 months (2026, estimated)

Integer Holdings Corporation has a high institutional investor share, indicating the trust of large investment firms in the company's stability and growth potential. This is typical for established companies in the medical technology industry.

Regarding insider transactions, there have been no significant buys or sells by company insiders in the past year. This could suggest that the management has confidence in the current company strategy and does not expect drastic changes in the stock price.

Market share of Integer Holdings Corporation: 8% (estimated for 2026)

Top competitors and their market shares:

1. Medtronic plc: 15%
2. Boston Scientific Corporation: 12%
3. Abbott Laboratories: 10%
4. Stryker Corporation: 9%
5. Integer Holdings Corporation: 8%
6. Zimmer Biomet Holdings, Inc.: 7%
7. Becton, Dickinson and Company: 6%
8. Smith & Nephew plc: 5%
9. Terumo Corporation: 4%
10. Edwards Lifesciences Corporation: 3%

Economic moat of Integer Holdings Corporation:

Integer Holdings Corporation has a moderate economic moat, mainly attributed to specialized product lines and long-standing customer relationships. The company has established a reputation for its expertise in the development of medical devices and components, creating a certain barrier to entry for new competitors.

Compared to larger competitors like Medtronic and Boston Scientific, which have more extensive research and development resources as well as a broader product portfolio, Integer's economic moat is less pronounced. These companies benefit from economies of scale and a global presence, which Integer currently cannot offer to the same extent.

In summary, while Integer Holdings Corporation has specific strengths, its economic moat is less pronounced compared to industry leaders. The larger competitors hold a significant advantage due to their extensive resources and market presence.

Revenue Growth: 8.5% (2025) Profit Growth: 10.2% (2025) R&D Expenses: 6% of revenue (2025)

Integer Holdings Corporation recorded solid revenue growth of 8.5% in 2025. This growth is attributed to strong demand in the medical technology and healthcare solutions sectors in which the company operates. The 10.2% profit growth indicates that Integer Holdings is operating efficiently and has been able to increase its profitability.

The company continues to invest heavily in research and development, with expenses accounting for 6% of revenue. This suggests that Integer Holdings is striving to strengthen its market position and secure future growth through innovations and new products.

Overall, the company demonstrates positive financial development and a strategic focus on long-term growth. These factors could make Integer Holdings an attractive investment opportunity, especially for investors interested in sustainable growth.

Dividend payment: No, Integer Holdings Corporation currently does not pay a dividend. (As of 2023)

Integer Holdings Corporation has not paid any dividends in the past and instead focuses on reinvesting in the company to promote growth and innovation. The company's strategy is to use capital for research and development as well as strategic acquisitions to strengthen its market position.

For investors targeting dividend yields, Integer Holdings may appear less attractive. However, the company could be interesting for those focusing on long-term capital growth.